Gambogic acid inhibits LPS-induced macrophage pro-inflammatory cytokine production mainly through suppression of the p38 pathway

Jianjun Ma 1, 2, Kangmao Huang 1, 2, Yan Ma 1, 2, Shuai Chen 1, 2, Chao Liu 1, 2, Zhi Shan 1, 2, Xiangqian Fang 1, 2*

1 Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou, China
2 Sir Run Run Shaw Institute of Clinical Medicine of Zhejiang University, Hangzhou, China

ARTICLE INFO

Objective(s): In traditional Chinese medicine, gamboge can detoxify bodies, kill parasites, and act as a hemostatic agent. Recent studies have demonstrated that gambogic acid (GBA) suppressed inflammation in arthritis, and also presented antitumor effect. Thus, this study investigated the new biological properties of GBA on macrophages.

Materials and Methods: RAW 264.7 cells were pretreated with GBA at different concentrations (10, 20, 40, 80, 160, 320 nM) for 24 hrs, and then cell viability was measured using Cell Counting Kit (CCK)-8 assays. Pro-inflammatory cytokines such as TNF-α, IL-6 and IL-1β were determined using ELISA kits and qPCR. Then nitric concentration was calculated according to a standard curve. At last, the effect of GBA on MAPK and NF-κB signaling pathways was assessed by western blot and luciferase reporter gene assay.

Results: GBA (IC50: 260 nM) suppressed the TNF-α, IL-6 and IL-1β expression induced by lipopolysaccharide (LPS) in RAW 264.7 cells. The expression of TNF-α, IL-6 and IL-1β decreased to 30-50% and 70-75% in the high-dose (160 nM) and low-dose (40 and 80 nM) GBA groups, respectively. Furthermore, the nitric oxide (NO) production and the activation of NF-κB, ERK, and JNK pathways were significantly reduced in high-dose (160 nM) GBA only, while p38 pathway was inhibited at both low (40 and 80 nM) and high (160 nM) concentration of GBA.

Conclusion: These data suggested that GBA inhibited LPS-induced production of pro-inflammatory cytokines including TNF-α, IL-6 and IL-1β mainly through the suppression of the p38 pathway.

Keywords: Anti-inflammatory agents
Gambogic acid
MAPK
NF-κB
p38
RAW 264.7 cells

Introduction

Periodontitis is an inflammatory response mainly induced by bacterial pathogens (1, 2). Lipopolysaccharide (LPS) is a key mediator of the inflammatory response and it can stimulate macrophages to release cytokines that promote inflammatory responses, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) (3). LPS induces the inflammatory reaction in macrophages via the activation of nuclear factor-kB (NF-kB) and mitogen-activated protein kinase (MAPK) pathways, including extracellular signal-regulated kinases (ERK), c-Jun N-terminal kinase (JNK) and p38 pathways (4-7). A previous review reported that the p38 pathway plays a key role in the orchestration of the inflammatory response in macrophages (6) and performs an important function in the control of TNF-α gene expression (6). Thus, the LPS-stimulated RAW 264.7 cells are an excellent model to screen candidate compound targeted in the inflammatory pathways (5). Gambogic acid (GBA) is an active agent extracted from gamboges (8), and has been used as an antitumor compound in China (9, 10). Furthermore, GBA also suppresses inflammation in rats with rheumatoid arthritis and spinal cord injury (11, 12). Thus, we identified GBA as a promising drug for the treatment of patients with periodontal diseases through the inhibition of inflammation. Here, we investigated the mechanism by which GBA inhibits LPS-induced release of pro-inflammatory factors in RAW 264.7 macrophages.

Materials and Methods

Tested compounds and chemicals

Mouse RAW 264.7 cells were purchased from the American Type Culture Collection (Rockville, MD). Porphyromonas gingivalis LPS was purchased from InvivoGen (Cayla, France). Alpha modification of Eagles medium (α-MEM) and fetal bovine serum (FBS) were obtained from Gibco-BRL (Sydney, Australia). GBA was purchased from Herbest (Baoji, Shanxi China) and dissolved in dimethylsulfoxide (DMSO). Griess Reagent was purchased from Promega (USA). The Prime Script RT reagent kit and SYBR Premix Ex Taq™ II were purchased from TaKaRa Biotechnology (Otsu, Shiga, Japan). Mouse TNF-α, IL-6 and IL-1 ELISA kits were purchased from Biologend Co. (San Diego, California, USA). Antibodies against phospho-ERK1/2, ERK1/2, phospho-JNK1/2, JNK1/2, and IκB-α were purchased from Cell Signaling (Danvers, MA). Cell Counting Kit (CCK)-8 kit was obtained from Dojindo Molecular Technology (Kumamoto, Japan). All other chemicals and

*Corresponding author: Fang Xiangqian, Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou, China. Tel: +86-13732224231; Fax: +86-57186048817; Email: xiangqian_fangsrr@163.com
reagents were purchased from Sigma (USA).

**Cell culture and treatment**

RAW 264.7 cells were cultured in complete α-MEM medium (α-MEM containing 10% heat inactivated FBS and 1% penicillin-streptomycin solution) in a humidified incubator with 5% CO₂ at 37 °C. The cells were pretreated with different concentrations of GBA and stimulated with LPS (100 ng/ml) for the indicated times. GBA was dissolved in DMSO, and the final concentration of DMSO was less than 0.1%.

**Assay of cell viability**

RAW 264.7 cells were plated in 96-well plates at the density of 2×10⁴ cells/well overnight. The cells were pretreated with GBA at the different concentrations (10, 20, 40, 80, 160, 320 nM) for 24 hrs. Then, 10 μl of CCK-8 buffer was added to each well and the cells were incubated at 37 °C for another 2 hrs, after which the absorbance was measured at 450 nm (650 nm reference) on an ELX800 absorbance microplate reader (Bio-Tek, Winooski, VT, USA). Cell viability was calculated relatively to that of the control group from the optical density (OD) by using the following formula: Cell viability = experimental group optimal density OD – reference OD/control group OD – reference OD.

**ELISA for TNF-α, IL-6 and IL-1β**

RAW 264.7 cells were seeded in a 6-well plate with a density of 1×10⁶ cells per well. The cells were pretreated with the indicated concentration of GBA for 2 hrs and then exposed to LPS (100 ng/ml) for 24 hrs. The expression of TNF-α, IL-6 and IL-1β in the supernatants were determined using ELISA kits according to the manufacturer’s instructions.

**RNA extraction and quantitative real-time PCR (RT-qPCR)**

RAW 264.7 cells were pretreated with the indicated concentration of GBA for 2 hrs and then exposed to LPS (100 ng/ml) for 4 hrs. Total RNA was extracted using Qiagen RNeasy Mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. cDNA was synthesized from 1000 ng of total RNA using reverse transcriptase (TaKaRa Biotechnology, Otsu, Japan). RT-qPCR was performed on an ABI 7500 Sequencing machine (Applied Biosystems, Foster City, CA, USA) using the SYBR Premix Ex Taq kit (TaKaRa Biotechnology) with the following cycling program: 40 cycles of denaturation at 95 °C for 5 sec and 34 sec of amplification at 60 °C. The following mouse primer sequences were used for RT-qPCR (Table 1):

**Nitrite determination**

The RAW 264.7 cells (2×10⁴ cells/well) were pretreated with GBA by the fore-mentioned different concentrations for 2 hr then followed by LPS (100 ng/ml) for a further 24 hr to estimate the nitrite concentrations in the supernatant using the Griess Reagent System. For this purpose, 50 μl of supernatant was reacted with 50 μl of sulfanilamide solution and 50 μl of NED solution. Absorbance was measured at a wavelength of 540 nm after incubation for 15 min at room temperature. A standard curve of nitrite concentrations was generated according to the manufacturer’s instructions, and nitrite concentration was calculated using the standard curve.

**NF-κB luciferase reporter gene assays**

To determine whether GBA could affect the NF-κB signaling pathway, RAW 264.7 cells were stably transfected with an NF-κB luciferase reporter construct as previously described (13). Briefly, RAW 264.7 cells were seeded in a 24-well plate at a density of 1×10⁵ cells/well. Cells were pretreated with different concentration of GBA for 2 hrs and then stimulated with LPS (100 ng/ml) for 6 hrs. The luciferase activity was measured using the Promega Luciferase Assay System according to the manufacturer’s instructions.

**Western blot analysis**

RAW 264.7 cells were seeded in a 6-well plate at 1×10⁶ cells/well and pretreated with the indicated concentration of GBA for 2 hrs, followed by LPS (100 ng/ml) stimulation for 30 min (NF-κB and MAPK assays) or 24 hr (inducible nitric oxide synthase, iNOS assay). Western blotting was performed as previously described (14). Membranes were blocked with 5% bovine serum albumin (BSA) for 1 hr and incubated with the indicated primary antibody at 4 °C overnight. After washing three times with Tris-buffered saline with Tween 20 (TBST) buffer, the membranes were incubated with the appropriate secondary antibody for 1 hr at room temperature. The blots were visualized using an Odyssey infrared imaging system (Li-COR).

**Statistical analysis**

All values are presented as the mean ± standard deviation (SD), and each experiment was performed in triplicate. Student’s t-test was used to determine whether there were statistically significant differences between groups. A P-value<0.05 was considered as significant difference.

**Results**

**The effect of GBA on cells growth and viability**

To assess the effect of GBA on RAW 264.7 cells, we...
first measured cell viability using a CCK-8 kit. As shown in Figure 1A, cell viability was not affected by GBA within 24 hr at 160 nM of GBA. However, obvious cytotoxicity was observed when RAW 264.7 cells were treated with 320 nM GBA. The calculated IC50 of GBA for this cell line was 260 nM (Figure 1B).

**GBA effect on the release and expression of pro-inflammatory cytokines**

To investigate the effect of GBA on LPS-induced pro-inflammatory cytokine release, RAW 264.7 cells were pretreated with different concentrations of GBA for 2 hr, followed by treatment with 100 ng/ml LPS for 24 hr. As shown in Figure 1, LPS significantly increased the expression of TNF-α, IL-6 and IL-1β at secreted protein level (Figure 1C, E and G). In contrast, GBA suppressed the expression of TNF-α, IL-6 and IL-1β (Figure 1C, E and G). The 160 nM of GBA attenuated the release of TNF-α to baseline levels approximately (Figure 1C). To determine whether the amount of pro-inflammatory cytokines changed at the transcript level, we also analyzed the mRNA expression profiles of TNF-α, IL-6 and IL-1β in LPS-stimulated RAW 264.7 cells. Consistent with our ELISA results, GBA markedly attenuated LPS-induced TNF-α, IL-6 and IL-1β mRNA expression (Figure 1D, F and H). Taken together, these data suggested that GBA suppresses the production of LPS-induced pro-inflammatory cytokines at both protein and mRNA level with non-cytotoxic doses.

**Changes in NO production, iNOS and NF-κB expression**

Nitric oxide (NO) is a key mediator of inflammation (15, 16) and has been demonstrated that it promotes the expression of pro-inflammatory mediators in LPS-stimulated RAW 264.7 cells (15, 17). Thus, we investigated the inhibitory effect of GBA on pro-inflammatory production release via decreasing the production of NO. It was found that the nitrite (NO2−) in the supernatant was inhibited by GBA at 80 and 160 nM (Figure 2A). Western bolt analysis confirmed that 160 nM of GBA significantly repressed the expression of iNOS (Figure 2B). Furthermore, the activation of NF-κB pathway can increase iNOS expression and NO production, which was previously reported (18). Thus, we examined the activation of the NF-κB signaling pathway after treatment of GBA. As shown in Figure 2C, LPS significantly activated NF-κB pathway in RAW 264.7 cells, which have been stably transfected with an NF-κB luciferase reporter construct. However, the activation of NF-κB pathway was suppressed by GBA at 160 nM (Figure 2C). The result of Western blot confirmed that 160 nM GBA significantly suppressed the LPS-induced
degradation of IκB-α (Figure 2D).

Interestingly, GBA did not alter the expression of NO and iNOS at low concentrations (20, 40, and 80 nM) (Figure 2A and B). Consistently, the NF-κB pathway remained active in response to low concentrations of GBA (40 nM), as demonstrated in Figure 2C and D. Therefore, high concentration of GBA (160 nM) inhibited NF-κB activation and suppressed iNOS and NO expression in LPS-stimulated RAW 264.7 cells.

Suppression of p38 pathway

To elucidate the mechanisms underlying the ability of low concentrations of GBA to inhibit the release of pro-inflammatory mediators, we explored the MAPK signaling pathways in LPS-stimulated RAW 264.7 cells by Western blot analysis. Interestingly, a low concentration of GBA (40 nM) significantly inhibited the phosphorylation of p38 (Figure 3A). In contrast, other
Gambogic acid inhibits inflammation in macrophages

MAPK signaling pathways including phosphorylation of ERK1/2 and JNK1/2 were only inhibited in response to 160 nM of GBA (Figure 3B and C). Taken together, GBA could inhibit p38 activation at low concentration (40 nM) and it displayed inhibitory effect on NF-κB, ERK and JNK activation at high concentrations (160 nM).

Discussion

GBA is a major active component extracted from resin of *Garcinia hanburyi* and *Garcinia morella* in Southeast Asia (8, 10). Previous studies reported that GBA has anticancer effects against lung cancer (19), leukemia (9), breast cancer (20), gastric cancer (21) and hepatocarcinoma (22). Thus, GBA has been approved for use as an antitumor compound in China (8). Recently, GBA was reported to suppress inflammation in arthritis (11, 12, 23) and inhibit osteoclast formation and ovariectomy-induced osteoporosis by suppressing the JNK, p38 and Akt signaling pathway (24). This study demonstrated that GBA suppressed the production of pro-inflammatory mediator induced by LPS at both the transcriptional and translational levels. Further studies demonstrated that LPS-induced activation of p38 was inhibited by GBA with the low concentration (40 nM). In addition, high concentration (160 nM) of GBA inhibited the activation of NF-kB pathway and downregulated the expression of iNOS and NO. Furthermore, high concentration of GBA (160 nM) inhibited the activation of ERK and JNK pathways. The expression of IL-6 and IL-1β is mainly regulated by p38 pathway (25), which may account for the similar effect of GBA on the protein levels of IL-6 and IL-1β with different concentrations (Figure 1E and 1G).

Periodontitis is an inflammatory disease caused by pathogenic bacteria. Moreover, pro-inflammatory mediators, such as IL-1 and TNF-α, play a critical role in this disease (26). Recent studies also reported that the expression of IL-6 contributed to the progress of chronic periodontitis (27, 28). These observations of inflammatory reaction were consistent with our results of LPS-induced RAW 264.7 cells. Activation of p38 signaling pathway is crucial for gene expression of pro-inflammatory mediators (29-31). Previous studies demonstrated that p38 inhibitors significantly decrease both the protein and mRNA levels of pro-inflammatory mediators (32). Kotlyarov et al. reported that knockout of MAPKAP kinase 2 (MK2), a downstream target of p38, suppressed LPS-induced overexpression of TNF-α, IL-6 and IL-1β, which demonstrated the importance of the p38 signaling pathway for pro-inflammatory factor production (33). Here, we reported that low concentrations of GBA (40 nM) markedly inhibit the phosphorylation of p38, which explains how GBA inhibits the release of TNF-α, IL-6 and IL-1β.

Although the NF-κB signaling pathway and other two MAPK pathways were not significantly inhibited by low concentration of GBA, other studies demonstrated that GBA could inhibit the activation of ERK signaling and JNK signaling pathway in pancreatic cancer cells (34) and osteoclast formation (24), respectively. The inhibitory effect of GBA on NF-κB signaling pathway could also be found in lung metastasis (35). Furthermore, a previous report indicated that GBA (500 nM) inhibited the release of pro-inflammatory mediators by blocking the NF-κB signaling pathway (36). Consistent with their results, we observed that high concentration of GBA (160 nM) inhibited the NF-κB signaling pathway and suppressed the expression of iNOS and NO. Moreover, high concentrations of GBA (160 nM) suppressed the activation of ERK, JNK and p38 pathways. Thus GBA elicited inhibitory effect on various signaling pathways, including the NF-κB and MAPK pathways.

To identify natural compounds that prevent the LPS-induced inflammatory response, we identified GBA as an antagonist of LPS-induced pro-inflammatory cytokines. Interestingly, a low concentration (40 nM and 80 nM) of GBA significantly suppressed the p38 pathway, and a high concentration (160 nM) of GBA only suppressed the NF-κB and other MAPK pathways (ERK and JNK). Taken together, our data demonstrates that GBA inhibits the release of TNF-α, IL-1β and IL-6 mainly through suppression of the P38 pathway (Figure 4).

Conclusion

This study demonstrated that GBA is a potential pro-inflammatory inhibitor due to the suppression of p38 pathway. In addition, the inhibition of NF-κB and other MAPK signaling pathways at high concentrations of GBA (160 nM) has an additive inhibitory effect on pro-inflammatory factor release. Given the importance of pro-inflammatory factor production in periodontitis and the potent inhibitory effect of GBA on inflammation, GBA is a promising compound for the treatment of periodontitis disease. Further studies are planned to test the efficacy of GBA in vivo.
Conflicts of Interest

The authors report no declarations of interest.

Acknowledgment

The study was sponsored by National Nature Science Fund of China [81171739, 81101378, 81271971, 81271972, 31270997], Natural Science Fund of Zhejiang Province (Y2110372), funds of science and technology department of Zhejiang Province (2009C03014-1), and Zhejiang provincial program for the cultivation of high-level innovative health talents. No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript.

References

1. Bartold PM, Cantley MD, Haynes DR. Mechanisms and control of pathologic bone loss in periodontitis. Periodontology 2010;53:55-69.
2. Yu H, Li Q, Herbert B, Zinna R, Martin K, Junior CR, et al. Anti-inflammatory effect of MAPK phosphatase-1 local gene transfer in inflammatory bone loss. Gene Ther 2011;18:344-353.
3. Adams DO, Hamilton TA. The cell biology of macrophage activation. Annu Rev Immunol 1984;2:283-318.
4. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 2008;42:145-151.
5. Kim KN, Heo SJ, Yoon WJ, Kang SM, Ahn G, Yi TH, et al. Fucocinobufalin inhibits the inflammatory response by suppressing the activation of NF-kappaB and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophages. Eur J Pharmacol 2010;649:369-375.
6. Bode JG, Ehlting C, Haussinger D. The macrophage response towards LPS and its control through the p38(MAPK)-STAT3 axis. Cell Signal 2012;24:1185-1194.
7. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001;13:85-94.
8. Han QB, Cheung S, Tai J, Qiao CF, Song JZ, Xu HX. Stability and cytotoxicity of gambogic acid and its derivative, gambogic acid. Biol Pharm Bull 2005;28:2335-2337.
9. Chen J, Zhou M, Zhang Q, Xu J, Ouyang J. Anticancer effect and cytotoxicity of gambogic acid. Biol Pharm Bull 2005;28:2335-2337.
10. Fu Q, Li C, Yu L. Gambogic acid inhibits spinal cord injury and resolution of inflammation. J Leukoc Biol 2011;88:1211-1220.
11. van der Vliet A, Eisensch JP, Cross CE. Nitric oxide: a pro-inflammatory mediator in lung disease? Respir Res 2000;1:67-72.
12. Maa MC, Chang MY, Chen YJ, Lin CH, Yu CJ, Yang YL, et al. Requirement of inducible nitric-oxide synthase in lipopolysaccharide-mediated Src induction and macrophage migration. The Journal of biological chemistry 2008;283:31408-31416.
13. Wang C, Wang W, Wang C, Tang Y, Tian H. Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer. Oncol Lett 2015;10:2063-2066.
14. Daddapaneni R, Patel K, Owaid IH, Singh M. Tumor neovascularization-targeted cationic PEGLysated liposomes of gambogic acid for the treatment of triple-negative breast cancer. Drug Deliv 2016;23:1232-1241.
15. Yu J, Guo QL, You QD, Zhao L, Gu HY, Yang Y, et al. Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDC2-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis 2007;28:632-638.
16. Yin D, Yang Y, Cai H, Wang F, Peng D, He L. Gambogic acid-loaded electrosprayed particles for site-specific treatment of hepatocellular carcinoma. Mol Pharm 2014;11:4107-4117.
17. Cascão R, Vidal B, Raquel H, Neves-Costa A, Figueiredo N, Gupta V, et al. Potent anti-inflammatory and anti proliferative effects of gambogic acid in a rat model of antigen-induced arthritis. Mediators of Inflammation 2014;2014:193527.
18. Ma J, Ma Y, Liu X, Chen S, Liu C, Qin A, et al. Gambogic acid inhibits osteoclast formation and bone resorption in osteoporosis by suppressing the JNK, p38 and Akt signaling pathways. Biochem J 2015;469:399-408.
19. Ahmed ST, Mayer A, Ji JD, Ivashkov LB. Inhibition of IL-6 signaling by a p38-dependent pathway occurs in the absence of new protein synthesis. J Leukoc Biol 2002;72:154-162.
20. Ossola CA, Surkin PN, Pugnaloni A, Mohn CE, Elverd J, Fernandez-Solar J. Long-term treatment with methanandamide attenuates LPS-induced periodontitis in rats. Inflamm Res 2012;61:941-948.
21. Zheng XY, Mao CY, Qiao H, Zhang X, Yu L, Wang Y, et al. Plumbagin suppresses chronic periodontitis in rats via down-regulation of TNF-alpha, IL-1beta and IL-6 expression. Acta Pharmacol Sin 2017;38:1150-1160.
22. Kobayashi T, Ishida K, Yoshie H. Increased expression of interleukin-6 in human rheumatoid arthritis patients with chronic periodontitis. Arch Oral Biol 2016;69:89-94.
23. van den Blink B, Juffermans NP, ten Hove S, Schultz MJ, van Deventer SJ, van der Poll T, et al. p38 mitogen-activated protein kinase inhibition increases cytokine release by macrophages in vitro and during infection in vivo. J Immunol 2001;166:582-587.
24. Lappas M, Permezel M, Rice GE. Mitogen-activated protein kinase pathways regulate LPS-stimulated release of pro-inflammatory cytokines and prostaglandins from human gestational tissues. Placenta 2007;28:936-945.
25. Anton L, Brown AG, Parry S, Elovitz MA. Lipopolysaccharide induces cytokine production and decreases extravillous trophoblast invasion through a mitogen-activated protein kinase-mediated pathway: possible mechanisms of first trimester placental dysfunction. Human Reproduction 2012;27:61-72.
26. Eckert RE, Neuder LE, Bell JL, Trujillo JC, Jones SL. The role
of p38 mitogen-activated kinase (MAPK) in the mechanism regulating cyclooxygenase gene expression in equine leukocytes. Vet Immunol Immunopathol 2007;118:294-303.

33. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HD, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nature Cell Biol 1999;1:94-97.

34. Xia G, Wang H, Song Z, Meng Q, Huang X, Huang X. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2). J Exp Clin Cancer Res 2017;36:107-120.

35. Zhao K, Zhang S, Song X, Yao Y, Zhou Y, You Q, et al. Gambogic acid suppresses cancer invasion and migration by inhibiting TGFbeta1-induced epithelial-to-mesenchymal transition. Oncotarget. 2017;8:27120-27136.

36. Palempalli UD, Gandhi U, Kalantari P, Vunta H, Arner RJ, Narayan V, et al. Gambogic acid covalently modifies IkappaB kinase-beta subunit to mediate suppression of lipopolysaccharide-induced activation of NF-kappaB in macrophages. Biochem J 2009;419:401-409.